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Abstract
Background: Dermatomyositis (DM) and polymyositis (PM) are rare systemic autoimmune rheumatic diseases with
high fatality rates. There have been few population-based mortality studies of dermatomyositis and polymyositis in
the world, and none have been conducted in Brazil. The objective of the present study was to employ multiple-
cause-of-death methodology in the analysis of trends in mortality related to dermatomyositis and polymyositis in
the state of São Paulo, Brazil, between 1985 and 2007.
Methods: We analyzed mortality data from the São Paulo State Data Analysis System, selecting all death
certificates on which DM or PM was listed as a cause of death. The variables sex, age and underlying, associated or
total mentions of causes of death were studied using mortality rates, proportions and historical trends. Statistical
analysis were performed by chi-square and H Kruskal-Wallis tests, variance analysis and linear regression. A p value
less than 0.05 was regarded as significant.
Results: Over a 23-year period, there were 318 DM-related deaths and 316 PM-related deaths. Overall, DM/PM was
designated as an underlying cause in 55.2% and as an associated cause in 44.8%; among 634 total deaths females
accounted for 71.5%. During the study period, age- and gender-adjusted DM mortality rates did not change
significantly, although PM as an underlying cause and total mentions of PM trended lower (p < 0.05). The mean
ages at death were 47.76 ± 20.81 years for DM and 54.24 ± 17.94 years for PM (p = 0.0003). For DM/PM,
respectively, as underlying causes, the principal associated causes of death were as follows: pneumonia (in 43.8%/
33.5%); respiratory failure (in 34.4%/32.3%); interstitial pulmonary diseases and other pulmonary conditions (in
28.9%/17.6%); and septicemia (in 22.8%/15.9%). For DM/PM, respectively, as associated causes, the following were
the principal underlying causes of death: respiratory disorders (in 28.3%/26.0%); circulatory disorders (in 17.4%/
20.5%); neoplasms (in 16.7%/13.7%); infectious and parasitic diseases (in 11.6%/9.6%); and gastrointestinal disorders
(in 8.0%/4.8%). Of the 318 DM-related deaths, 36 involved neoplasms, compared with 20 of the 316 PM-related
deaths (p = 0.03).
Conclusions: Our study using multiple cause of deaths found that DM/PM were identified as the underlying cause
of death in only 55.2% of the deaths, indicating that both diseases were underestimated in the primary mortality
statistics. We observed a predominance of deaths in women and in older individuals, as well as a trend toward
stability in the mortality rates. We have confirmed that the risk of death is greater when either disease is
accompanied by neoplasm, albeit to lesser degree in individuals with PM. The investigation of the underlying and
associated causes of death related to DM/PM broaden the knowledge of the natural history of both diseases and
could help integrate mortality data for use in the evaluation of control measures for DM/PM.
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Background
Dermatomyositis and polymyositis are rare systemic
autoimmune rheumatic diseases characterized by
chronic inflammatory myopathies. Both diseases involve
an immune process that is triggered by environmental
factors in genetically susceptible individuals, although
the etiopathogenesis remains unknown [1]. Before mod-
ern treatments became available, the fatality related to
these conditions was as high as 50-70% [2]. Currently
reported fatality ratios vary widely–from 2% to 45%
[3,4].
Studies on the impact of rheumatic diseases should
include mortality data as a complement to those regard-
ing functional status, work capacity and overall quality
of life [5]. One limitation of the majority of studies on
mortality in myositis is that they involve cohorts that
are small or are followed at single medical facilities, and
there have been few population-based studies on the
topic [4]. Only specialized facilities accumulate a suffi-
cient number of patients to analyze the mortality related
to diseases such as polymyositis [6]. The analysis of
mortality statistics was considered the principal means
of determining the frequency of dermatomyositis and
other connective tissue diseases [7]. A study conducted
in Finland demonstrated that mortality rates were three
times higher in patients with dermatomyositis or poly-
myositis than in a group of age- and gender-matched
individuals of the population [4,8]. In the Netherlands,
the 5-year risk of death for myositis patients was shown
to be 11%, compared with 1-2% for individuals of the
same mean age of the Dutch population [3,4].
In Brazil, mortality statistics are derived from death
certificates, which are provided by physicians or are cre-
ated based on witness statements, requiring notarization
in either case [9-11]. Copies of the death certificates are
sent to the state bureaus of vital statistics or depart-
ments of epidemiological surveillance, where the demo-
graphic and medical data are encoded and processed,
the resulting data sets then being forwarded to the Bra-
zilian Ministry of Health for consolidation at the
national level [12]. Among those data, considerable
importance is given to the causes of death. The underly-
ing cause of death is defined as “(a) the disease or injury
which initiated the train of morbid events leading
directly to death; or (b) the circumstances of the accident
or violence which produced the fatal injury“ [13]. With
the objective of preventing deaths, the underlying cause
is presented in the so-called primary mortality statistics.
Despite the value of knowing the underlying cause,
there has been, since the mid-20th century, an increas-
ing demand for taking into account all of the causes of
death listed on death certificates. This methodology,
designated multiple cause of death analysis, furnishes
information regarding all of the conditions and circum-
stances involved in the process that culminated in
death, offering new elements and perspectives for pre-
vention [14,15]. Multiple cause of death analysis is parti-
cularly recommended for the study of the mortality in
chronic diseases, such as rheumatic diseases [16,17].
Data related to multiple causes of death have been avail-
able for the state of São Paulo since 1983 and for Brazil
as a whole since 1999 [14,18,19].
The objective of the present study was to employ mul-
tiple cause of death analysis in the study of trends in
mortality related to dermatomyositis and polymyositis in
the state of São Paulo between 1985 and 2007.
Methods
The annual mortality data were obtained from the pub-
licly available databases of the Sistema Estadual de Aná-
lise de Dados (SEADE, State Data Analysis System)
Foundation, the organ responsible for vital statistics,
operating under the auspices of the São Paulo State
Secretary of Economics and Planning. We selected all
deaths in which dermatomyositis or polymyositis were
listed on any line or in either part of the International
Form of Medical Certificate of Cause of Death (the
medical certification section of the death certificate),
whether categorized as the underlying cause of death or
as an associated (non-underlying) cause. Complications
of the underlying cause (Part I of the medical certifica-
tion section) and contributing causes (Part II of the
medical certification section) were collectively desig-
nated associated causes of death. We employed the
1985-2007 annual population estimates for the state of
São Paulo, which were recently updated by the SEADE
Foundation [20]. Those data, based on the 2007 Census,
reveal trends in the demographic components of the
vital statistics (updated through 2007) and the changes
in population growth.
We selected all deaths in which one of the following
subcategories of the ninth or tenth revision of the Inter-
national Classification of Diseases (ICD-9 or ICD-10)
were listed [21,22]: 710.3 (ICD-9, Dermatomyositis);
710.4 (ICD-9, Polymyositis); M33.0 (ICD-10, Juvenile
dermatomyositis); M33.1 (ICD-10, Other dermatomyosi-
tis); M33.2 (ICD-10, Polymyositis); and M33.9 (ICD-10,
Dermatopolymyositis, unspecified). Equivalency tables
were constructed in order to compare the ICD-9 and
ICD-10 categories in terms of the trends in the causes
of death [23,24]. In order to reconstruct the morbid
process leading to death, all of the causes of death listed
in the medical certification section of the death certifi-
cate were considered, even those classified as ill-defined
and those characterized by the World Health Organiza-
tion (WHO) as modes of death [13].
Santo et al. BMC Public Health 2010, 10:597
http://www.biomedcentral.com/1471-2458/10/597
Page 2 of 14
The records included in the mortality databases con-
tain fields that mirror those appearing on the official
Brazilian death certificate. In the present study, it was
necessary to standardize the structure of the records
studied, since various fields on the death certificate had
been modified, in terms of designation, size and the
codes used in order to identify variables, between 1985
and 2007. In addition, we created auxiliary fields for the
study of multiple causes, including a field designed to
contain a single “string” of characters composed of the
codes entered on lines (a), (b), (c) and (d) of Parts I and
of Part II of the medical certification section of the
death certificate.
Between 1985 and 1995, the automatic processing of
data related to the causes of death was performed with
the Automated Classification of Medical Entities
(ACME) program [14,15,19,25-27], after which (between
1996 and 2007) it was performed with the Declarações
de Óbito de São Paulo (DOSP, São Paulo Death Certifi-
cates) program [28], an adaptation that allowed the data
to be processed in batches using the Underlying Cause
Selection program [19]. The data regarding the asso-
ciated causes of death in 1996 are incomplete due to the
fact that the SEADE Foundation implemented the use of
the DOSP in April of that year. The automatic proces-
sing involves the use of algorithms and decision tables
that incorporate the WHO mortality standards and the
etiological relationships among the causes of death. The
ACME decision tables [29,30] are considered de facto
international standards for the automatic processing of
data related to the causes of death [17,31]. The struc-
tural difference between the numeric codes employed in
the ICD-9 (used up through 1995) and the alphanu-
meric codes employed in the ICD-10 (in use since 1996)
affected the processing of the data in that a different
program was required for each coding system. As a con-
sequence, we studied the trends in mortality related to
dermatomyositis or polymyositis in two separate periods:
1985-1995 and 1996-2007. The expressions “death from”
and “death due to” refer to the underlying cause of
death, whereas “deaths with a mention of” and “mortal-
ity related to” refer to the listing of a given condition
either as the underlying cause or as an associated cause.
The causes of death evaluated in the present study were
those originally mentioned in the medical certification
section, internationally classified as “entity axis codes”,
which were defined and presented under the structure
and headings of the ICD [14,32].
Using mortality rates, proportions and historical
trends, we studied the distributions of the following
variables: gender; age at death; year of death; underlying
cause of death; associated cause(s) of death; total men-
tions of each cause of death; and mean number of
causes listed per death certificate. Medical and
demographic variables were processed with the follow-
ing programs: dBASE III Plus, version 1.1 (Ashton-Tate
Corporation, Torrance, CA), Epi Info, version 6.04d
(Centers for Disease Control and Prevention, Atlanta,
GA), Excel 2007 (Microsoft Corporation, Redmond,
WA) and Stata/IC for Windows, version 10 (Stata Corp
LP, College Station, TX). We used the Tabulador de
Causas Múltiplas (Multiple Causes Tabulator) program
(DATASUS, Ministério da Saúde, Faculdade de Saúde
Pública, Universidade de São Paulo, Brazil), available for
ICD-9 and ICD-10 (TCM-9, version 4.0; and TCM-10,
version 2.2), in our presentation of the associated causes
and of the mean number of causes per death certificate
[33]. For the presentation of the associated causes listed
on the death certificates on which dermatomyositis or
polymyositis were identified as the underlying cause, we
prepared special lists showing the causes involved in the
respective natural histories [1,34-38], as well as those
mentioned with the greatest frequency. The duplication
or multiplication of causes of death was avoided when
the causes were presented in abbreviated lists. The num-
ber of causes depends on the breadth of the class (sub-
category, category, grouping or chapter of the ICD-9 or
ICD-10). Therefore, if two or more causes mentioned in
the medical certification section were included in the
same class, only one cause was computed [14,33]. The
Separador de Registros de Mortalidade (SRM_DBF,
Mortality Records Separator_dBASE File) program
(DATASUS, Ministério da Saúde, Faculdade de Saúde
Pública, Universidade de São Paulo, Brazil), with ver-
sions for ICD-9 and ICD-10 (version 1.1 and version
3.1, respectively), was used in order to compile records
in which there was interest in specific associated causes
of death. The study of the joint mention among the
causes of death listed on the death certificates was per-
formed with the Tabulador de Causas Conjuntas (Joint
Causes Tabulator, version 1.3, for ICD-9 and ICD-10)
program. The ratio between the observed number of
cause-of-death pairs and the expected number of such
pairs, under the hypothesis of independence was calcu-
lated [14,15,17].
Mortality rates (per 1,000,000 population) for derma-
tomyositis and polymyositis were calculated–by year, by
subperiod and for the study period (1985-2007) as a
whole–based on the number of deaths in which each
disease had been identified as the underlying cause or as
an associated cause, as well as on the total number of
mentions of each disease. In order to calculate the mean
mortality rate for each subperiod studied, the number of
deaths occurring in the period was divided by the sum
of the respective annual population counts, analogous to
the procedure used in order to calculate the mean mor-
tality rate for the 23-year study period as a whole. The
Análisis Epidemiológico de Datos Tabulados (Epidat,
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Epidemiological Analysis of Tabulated Data) program,
version 3.1 (Pan American Health Organization; http://
dxsp.sergas.es) was used for standardize, by the direct
method, the age-adjusted crude and mean mortality
rates, by subperiod and for the study period as a whole,
to the population of Brazil in 2000.
Statistical analysis
We used the chi-square test in order to analyze joint
mentions and the associations between causes of death;
analysis of variance in order to compare the mean num-
bers of causes mentioned on the death certificate; the
Kruskal-Wallis H test in order to compare the mean age
at death between groups; and linear regression in order
to evaluate the magnitude and significance of historical
trends in the mean ages at death and the standardized
mortality rates. Values of p < 0.05 were considered
significant.
Results
In the state of São Paulo, there were 318 and 316 deaths
related to dermatomyositis and polymyositis, respec-
tively, between 1985 and 2007, totaling 634 deaths
(annual mean, 27.6 deaths). Among those 634 deaths,
one of the two diseases was listed as the underlying
cause in 350 (55.2%) and as an associated cause of death
in 284 (44.8%), resulting in annual means of 15.2 and
12.3 deaths, respectively. There was a marked annual
variation in the total number of dermatomyositis- or
polymyositis-related deaths, which ranged from 20 (in
1986) to 43 (in 1999), although the trend was to remain
close to the mean number. Death related to dermato-
myositis or polymyositis was more common among
women, who accounted for 453 (71.5%) of the 634
deaths. The majority (65.8%) of the dermatomyositis- or
polymyositis-related deaths occurred in individuals over
45 years of age, particularly in those between 55 and 64
years of age, who accounted for 22.2% of such deaths
(Table 1)
The linear regression showed that, in the period stu-
died, there were no significant variations in the standar-
dized mortality rates for dermatomyositis as an
underlying cause (p = 0.786), as an associated cause (p
= 0.741) or in terms of the total mentions (p = 0.684);
nor was there any such variation in the standardized
mortality rates for polymyositis as an associated cause of
death (p = 0.340). However, for the deaths related to
polymyositis, we observed significant decreases in the
standardized mortality rates, for polymyositis as the
underlying cause (p = 0.016), which fell from 0.3297/
1,000,000 population in 1985 to 0.2225/1,000,000 popu-
lation in 2007, as well as for the total mentions of poly-
myositis (p = 0.005), which fell from 0.6597/1,000,000
population in 1985 to 0.3669/1,000,000 population in
2007. Figures 1a and 1b show the trends in the standar-
dized mortality rates according to the causes of death in
dermatomyositis- or polymyositis-related deaths.
The female/male ratio for the standardized mean mor-
tality rates in the 23-year study period as a whole was
2.24:1 for all of the deaths studied, ranging from 3.07:1
for dermatomyositis as the underlying cause to 1.76:1
for polymyositis, as the underlying cause (Table 1).
Although the overall distribution between the genders
in terms of the underlying cause and associated causes
was similar to that observed for all of the deaths studied,
we found dermatomyositis as the underlying cause of
death to be more common among women, who
accounted for 139 (59.1%) of the 235 such deaths,
whereas men were more often the victims of fatal poly-
myositis, accounting for 57 (58.2%) of the 98 deaths in
which polymyositis was listed as the underlying cause
(Table 1).
The linear regression revealed no significant variations
in the standardized mortality rates by total mentions, of
dermatomyositis–in men (p = 0.267) or in women (p =
0.575)–or of polymyositis in women (p = 0.102), over the
course of the study period. However, there was a signifi-
cant decrease in the standardized mortality rate, by total
mentions, for polymyositis in men (p = 0.001), which fell
from 0.5078/1,000,000 population in 1985 to 0.1025/
1,000,000 population in 2007 (Figures 2a and 2b).
Considering the 23-year study period as a whole, we
found that the specific dermatomyositis- and polymyosi-
tis-related mortality rates were directly proportional to
the age group studied, following a unimodal distribution.
Consequently, the highest mortality rates were found in
the ≥ 75-year age bracket, except for dermatomyositis or
polymyositis as the underlying cause in men, for which
the highest mortality rates were in the 65- to 74-year
age bracket. In the ≤ 24-year age bracket, the underlying
cause of death was dermatomyositis in 67% (38 of the
57 deaths studied), as was also true for polymyositis (14
of the 21 deaths studied), compared with 54% (142 of
the 261 deaths studied) and 53% (156 of the 295 deaths
studied), respectively, in the ≥ 25-year age bracket
(Table 1).
Despite being influenced by the qualification of the
cause of death, the mean ages at death were consistently
lower among the deaths related to dermatomyositis than
among those related to polymyositis: as the underlying
cause–45.40 ± 21.20 and 52.68 ± 18.41 years, respec-
tively (p = 0.002822); as an associated cause–50.84 ±
19.95 and 56.06 ± 17.25 years, respectively (p =
0.039359); and as a mentioned cause–47.76 ± 20.81 and
54.24 ± 17.94 years, respectively (p = 0.000279). Like-
wise, the median and mode ages were lower among the
deaths related to dermatomyositis than among those
related to polymyositis (Table 1).
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The mean ages at death were also higher among
women than among men, whether death was attributed
to dermatomyositis (48.06 ± 20.98 vs. 46.89 ± 20.42
years) or to polymyositis (54.61 ± 18.20 vs. 53.42 ±
17.42), although the differences were not significant.
The linear regression showed that there were no sig-
nificant differences between 1985 and 2007 in terms of
the mean ages at death among the dermatomyositis-
related deaths in men and women (p = 0.172 and p =
0.081, respectively) or among the polymyositis-related
Table 1 Mortality related to dermatomyositis and polymyositis, according to the qualification of the cause-of-death,
absolute numbers and percentage of deaths, gender and age mean, crude, standardized and specific death rates,
mean, median and mode of the ages at death, state of São Paulo, Brazil. 1985 to 2007
Dermatomyositis Polymyositis Total mentions
Underlying Associated Mentions Underlying Associated Mentions Underlying Associated Mentions
GENDER. ABSOLUTE NUMBERS (%)
Male 41 (22.8) 42 (30.4) 83 (26.1) 57 (33.5) 41 (28.1) 98 (31.0) 98 (28.0) 83 (29.2) 181 (28.5)
Female 139 (77.2) 96 (69.6) 235 (73.9) 113 (66.5) 105 (71.9) 218 (69.0) 252 (72.0) 201 (70.8) 453 (71.5)
Total 180 (100.0) 138 (100.0) 318 (100.0) 170 (100.0) 146 (100.0) 316 (100.0) 350 (100.0) 284 (100.0) 634 (100.0)
MEAN CRUDE SPECIFIC DEATH RATES (PER 1.000.000 POPULATION) ACCORDING TO GENDER
Male 0.1054 0.1079 0.2133 0.1465 0.1054 0.2519 0.2519 0.2133 0.4652
Female 0.3460 0.2389 0.5849 0.2813 0.2614 0.5426 0.6272 0.5003 1.1275
Total 0.2276 0.1745 0.4021 0.2150 0.1846 0.3996 0.4426 0.3591 0.8017
MEAN STANDARDIZED SPECIFIC DEATH RATES (PER 1.000.000 POPULATION) ACCORDING TO GENDER
Male 0.1074 0.1082 0.2155 0.1494 0.1079 0.2572 0.2567 0.2160 0.4728
Female 0.3299 0.2249 0.5548 0.2629 0.2421 0.5050 0.5928 0.4670 1.0598
Total 0.2232 0.1705 0.3936 0.2096 0.1807 0.3902 0.4327 0.3511 0.7839
Ratio F/M 3.07 2.08 2.57 1.76 2.24 1.96 2.31 2.16 2.24
AGE IN YEARS. ABSOLUTE NUMBERS (%)
00-14 24 (13.3) 10 (7.2) 34 (10.7) 5 (2.9) 4 (2.7) 9 (2.8) 29 (8.3) 14 (4.9) 43 (6.8)
15-24 14 (7.8) 9 (6.5) 23 (7.2) 9 (5.3) 3 (2.1) 12 (3.8) 23 (6.6) 12 (4.2) 35 (5.5)
25-34 15 (8.3) 11 (8.00) 26 (8.2) 16 (9.4) 11 (7.5) 27 (8.5) 31 (8.9) 22 (7.7) 53 (8.4)
35-44 22 (12.2) 17 (12.3) 39 (12.3) 25 (14.7) 22 (15.1) 47 (14.9) 47 (13.4) 39 (13.7) 86 (13.6)
45-54 36 (20.0) 20 (14.5) 56 (17.6) 29 (17.1) 26 (17.8) 55 (17.4) 65 (18.6) 46 (16.2) 111 (17.5)
55-64 36 (20.0) 37 (26.8) 73 (23.0) 41 (24.1) 27 (18.5) 68 (21.5) 77 (22.0) 64 (22.5) 141 (22.2)
65-74 22 (12.2) 22 (15.9) 44 (13.8) 24 (14.1) 32 (21.9) 56 (17.7) 46 (13.1) 54 (19.0) 100 (15.8)
≥75 11 (6.1) 12 (8.7) 23 (7.2) 21 (12.4) 21 (14.4) 42 (13.3) 32 (9.1) 33 (11.6) 65 (10.3)
Total 180 (100.0) 138 (100.0) 318 (100.0) 170 (100.0) 146 (100.0) 316 (100.0) 350 (100.0) 284 (100.0) 634 (100.0)
MEAN SPECIFIC DEATH RATES (PER 1.000.000 POPULATION) ACCORDING TO AGE
00-14 0.1088 0.0453 0.1541 0.0227 0.0181 0.0408 0.1315 0.0635 0.1950
15-24 0.0939 0.0603 0.1542 0.0603 0.0201 0.0805 0.1542 0.0805 0.2347
25-34 0.1097 0.0804 0.1901 0.1170 0.0804 0.1974 0.2267 0.1609 0.3875
35-44 0.1979 0.1529 0.3509 0.2249 0.1979 0.4228 0.4228 0.3509 0.7737
45-54 0.4615 0.2564 0.7180 0.3718 0.3333 0.7051 0.8333 0.5897 1.4231
55-64 0.7185 0.7384 1.4569 0.8182 0.5388 1.3571 1.5367 1.2773 2.8140
65-74 0.7420 0.7420 1.4841 0.8095 1.0793 1.8888 1.5515 1.8214 3.3729
≥75 0.7113 0.7760 1.4873 1.3580 1.3580 2.7160 2.0693 2.1340 4.2033
AGES AT DEATH (YEARS)
Mean
(SD)
45.40 (±
21.20)
50.84 (±
19.95)
47.76 (±
20.81)
52.68 (±
18.41)
56.06 (±
17.25)
54.24 (±
17.94)
48.93 (±
20.20)
53.52 (±
18.76)
50.99 (±
19.69)
Median 49.00 56.00 51.50 55.50 57.50 56.50 52.50 57.00 54.50
Mode 52.50 64.50 64.50 61.50 61.50 61.50 42.50 61.50 61.50
Source: Fundação Sistema Estadual de Análise de Dados (SEADE)
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deaths in men (p = 0.538). Among the polymyositis-
related deaths in women, there was a temporal increase
in the age at death (p = 0.004), which rose from 45.32 ±
20.52 years in 1985 to 58.10 ± 20.06) years in 2007.
For the 23-year study period as a whole, the following
were the principal associated causes of death when the
underlying cause was identified as dermatomyositis or
polymyositis, respectively: pneumonia–in 43.3% and
33.5%; respiratory failure–in 34.4% and 32.4%; interstitial
lung disease and other respiratory diseases–in 28.9% and
17.6% (p = 0.013074); and septicemia–in 22.8% and
15.9%. Neoplasm occurred as an associated cause only
in the deaths attributed to dermatomyositis. (Table 2)
As shown in Table 3, the principal underlying causes
of death when dermatomyositis or polymyositis was
listed as an associated cause were, respectively, as fol-
lows: diseases of the respiratory system–in 29.0% and
26.0%; diseases of the circulatory system–in 17.4% and
20.5%; neoplasms–in 15.9% and 13.7%; certain infectious
and parasitic diseases–in 11.6% and 9.6%; diseases of the
digestive system–in 8.0% and 4.8%; and endocrine,
nutritional and metabolic disorders–in 4.3% and 8.9%.
Figure 1 Trends of death rates of dermatomyositis and polymyositis, underlying, associated and total causes of death, State of São
Paulo, Brazil, 1985 to 2007.
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In addition to the associations described above for
dermatomyositis and polymyositis as underlying or asso-
ciated causes, it is of note that, of the 634 death certifi-
cates, there were joint mentions of pneumonia and
septicemia on 84 (observed/expected ratio, 1.62) and of
pneumonia and respiratory failure on 73 (observed/
expected ratio, 1.41). Similarly, dermatomyositis and
polymyositis were mentioned jointly with systemic lupus
erythematosus on 5 and 8 of the death certificates,
respectively, systemic sclerosis on 3 and 9, respectively,
diffuse connective tissue diseases on 2 and 1, respec-
tively, and muscle disorders on 1 and 2, respectively. In
addition, dermatomyositis was mentioned jointly with
polymyositis and with juvenile chronic polyarthritis on 1
death certificate each, whereas polymyositis was men-
tioned jointly with rheumatoid arthritis on 8, with non-
specific arthritis on 1 and with scoliosis on 1.
For the two subperiods studied (1985-1995 and 1996-
2007), the mean number of causes of death per death
certificate among those listing dermatomyositis or poly-
myositis as the underlying cause was 2.98 ± 0.81 and 3.49
± 1.21, respectively, compared with 3.90 ± 1.01 and 4.22
± 1.05 among those listing either disease as an associated
cause. All of the differences between these means, two by
two, between the periods and between the qualifications
of the causes of death, were significant (p < 0.05).
Considering all of the causes of death listed, we found
that neoplasm co-occurred in 36 of the 318 deaths
Figure 2 Trends of death rates of dermatomyositis and polymyositis according to gender, State of São Paulo, Brazil, 1985 to 2007.
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related to dermatomyositis and in 20 of the 316 deaths
related to polymyositis. Therefore, the probability of
neoplasm was greater when death was related to derma-
tomyositis (c2 = 4.90; p = 0.026790), corresponding to a
relative risk of 1.79 (range, 1.07-3.04) between the
respective specific standardized mortality rates. In 1996,
the ICD-10 was introduced and juvenile dermatomyosi-
tis came to be classified separately in the subcategory
M33.0. Between 1996 and 2007, there were no joint
mentions of juvenile dermatomyositis and neoplasm on
any of the death certificates included in the present
study. The proportion of women was greater among the
deaths in which there was a joint mention of neoplasm
and dermatomyositis than among those in which there
was a joint mention of neoplasm and polymyositis, the
female/male ratios being 3.5 and 1.5, respectively,
although the differences were not significant. Of the 56
deaths in which neoplasm was mentioned jointly with
dermatomyositis or polymyositis, 49 (87.5%) occurred in
individuals ≥ 45 years of age. The mean age at death
among the deaths in which neoplasm was mentioned
jointly with dermatomyositis was of 61.50 ± 13.66 years,
significantly higher than the 46.00 ± 20.93 years
observed for dermatomyositis-related deaths in which
neoplasm was not mentioned (p = 0.0000). However, no
statistical differences were observed between polymyosi-
tis-related deaths with a joint mention of neoplasm and
those without in terms of the mean age at death, which
was 61.05 ± 15.81 and 53.78 ± 18.00 years, respectively
(p = 0.0744). The principal sites of the malignant neo-
plasms were the digestive tract, breasts, ovaries and
lungs, as well as the lymphoid, hematopoietic and
related tissues. There was one death in which polymyo-
sitis was mentioned jointly with polycythemia vera, a
neoplasm classified as being of uncertain or unknown
behaviour (Table 4)
Discussion
The present study revisits the issue of mortality related
to dermatomyositis and polymyositis 25 years after the
publication of the only analogous study on the topic
[39] and 37 years after mortality related to dermatomyo-
sitis was first studied in the United States [7]. The use
of multiple cause of death analysis is one of the princi-
pal characteristics and advantages of the present study.
The multiple cause of death analysis method was
employed in order to identify the greatest possible num-
ber of deaths related autoimmune diseases, which are
frequently mentioned as associated causes of death [16].
This occurred in the present study, in which dermato-
myositis or polymyositis was classified as an associated
cause in 44.8% of the deaths. The underestimation of
chronic rheumatic diseases in mortality statistics has
been attributed to the identification of one of their com-
plications, such as an acute process, inflammation, infec-
tion or cardiovascular diseases, that frequently becomes
the underlying cause of death [5,6]. Specifically, the
underestimation of dermatomyositis and polymyositis,
Table 2 Associated (non-underlying) causes in deaths related to dermatomyositis and polymyositis as an underlying
cause, state of São Paulo, 1985 to 2007
Associated (non-underlying) causes of death (ICD-9) (ICD-10) Dermatomyositis Polymyositis
(deaths = 180) (deaths = 170)
n % n %
Pneumonia (480.0-483, 485-486, 507.0) (J12.0-J16.8, J18.0-J18.9, J69.0) 78 43.3 57 33.5
Respiratory failure (7860) (J96) 62 34.4 55 32.4
Interstitial pulmonary disease and other pulmonary diseases (510-519) (J80-J95, J98) 52 28.9 30 17.6
Septicaemia (038.0-038.9) (A40.0-A41.9) 41 22.8 27 15.9
Hypertensive diseases and other heart diseases (401-427, 429) (I10-I49, I51) 21 11.7 21 12.4
Multiple organs failure (7998) (R688) 22 12.2 17 10.0
Heart failure (428.0-428.9) (I50.0-I50.9) 13 7.2 21 12.4
Cardiorespiratory failure (427.5, 799.1) (I46.9, R092) 11 6.1 22 12.9
Diabetes mellitus (250.0-250.9) (E10.0-E14.9) 15 8.3 11 6.5
Shock (785.5) (R57.0-R57.9) 13 7.2 11 6.5
Renal failure (584.5-586) (N17.0-N19) 5 2.8 15 8.8
Malnutrition/Cachexia (260.0-263.9, 799.4) (E40-E46, R64) 6 3.3 11 6.5
Neoplasms (140.0-239.9) (C00.0-D48.9) 13 7.2 0 0.0
Remaining associated causes of death 52 28.9 49 28.8
Source: Fundação Sistema Estadual de Análise de Dados (SEADE)
Percents calculated in relation to the number of deaths
Rubrics and codes of the International Classification of Diseases, Injuries and Causes of Death, Ninth Revision (1985 to 1995)
Rubrics and codes of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (1996 to 2007)
Data for 1996 are partial
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understood as associated causes of death, has been
attributed to their association with malignant neoplasms
[39].
The example of the underestimation of rheumatic dis-
eases in underlying-cause mortality statistics has been
employed as an argument for the broad use of multiple
cause of death analysis. The tabulation of half of the
deaths in the United States in 1955 revealed that
approximately 90% of the causes of death included in
the categories of arthritis and other rheumatic diseases
were not considered in the primary statistics, in which
rheumatoid arthritis was underestimated by approxi-
mately 85% and other types of arthritis were underesti-
mated by more than 90%, representing the extreme of
underestimation, in contrast with neoplasm, which was
underestimated by only 10% [7,40,41]. A study con-
ducted in Oxford, England evaluated the influence that
mortality coding rules and the introduction of automatic
data processing have had on mortality statistics [42].
The authors found that rheumatoid arthritis and other
inflammatory polyarthropathies were underestimated by
75.5%, 53.7% and 73.3% in the 1978-1983, 1984-1992
and 1993-1998 periods, respectively. In France, the
number of deaths related to rheumatoid arthritis in the
1970-2002 period nearly tripled when all death-certifi-
cate mentions of the disease were considered [17].
Over the 23-year period evaluated in the present
study, the dermatomyositis-related mortality rate did
not vary significantly, whereas the mortality rates for
polymyositis as the underlying cause and in terms of
total mentions decreased, this decrease being attributed
in part to a drop in the mortality rates for total men-
tions of polymyositis in men. There are currently no
parameters for the evaluation of the magnitude and
Table 3 Underlying causes in deaths related to dermatomyositis and polymyositis as an associated cause, state of São
Paulo, 1985 to 2007
Underlying causes of death (ICD-9) (ICD-10) Dermatomyositis Polymyositis Total
n % n % n %
Certain infectious and parasitic diseases (001-139) (A00-B99) 16 11.6 14 9.6 30 10.6
Tuberculosis (010-018) (A15-A19) 5 3.6 1 0.7 6 2.1
Septicaemia (038) (A40-A41) 4 2.9 4 2.7 8 2.8
Human immunodeficiency virus {HIV} disease (279.1) (B20-B24) 1 0.7 4 2.7 5 1.8
Neoplasms (140-239) (C00-D48) 23 16.7 20 13.7 43 15.1
Diseases of the blood and blood-forming organs and ... (280-289) (D50-D89) 8 5.8 5 3.4 13 4.6
Certain disorders involving the immune mechanism (279.0, 279.2-279,9) (D80-D89) 7 5.1 2 1.4 9 3.2
Endocrine, nutritional and metabolic diseases (240-278) (E00-E90) 6 4.3 13 8.9 19 6.7
Diabetes mellitus (250) (E10-E14) 1 0.7 8 5.5 9 3.2
Diseases of the nervous system (320-359) (G00-G98) 2 1.4 2 1.4 4 1.4
Diseases of the circulatory system (390-459) (I00-I99) 24 17.4 30 20.5 54 19.0
Hypertensive diseases (401-404) (I10-I13) 0 0.0 3 2.1 3 1.1
Ischaemic heart diseases (410-414) (I20-I25) 7 5.1 10 6.8 17 6.0
Cardiomyopathy (425) (I42) 4 2.9 4 2.7 8 2.8
Cerebrovascular diseases (430-438) (I60-I69) 1 0.7 5 3.4 6 2.1
Arteritis, phlebitis and thrombophlebitis (447.6, 451) (I77.6, I80) 0 0.0 1 0.7 1 0.4
Diseases of the respiratory system (460-519) (J00-J99) 39 28.3 38 26.0 77 27.1
Pneumonia (480-486) (J12-J18) 21 15.2 24 16.4 45 15.8
Diseases of the digestive system (520-579) (K00-K93) 11 8.0 7 4.8 18 6.3
Diseases of the skin and subcutaneous tissue (680-709) (L00-L99) 1 0.7 1 0.7 2 0.7
Diseases of the musculoskeletal system and connective tissue (710-739) (M00-M99) 5 3.6 10 6.8 15 5.3
Pyogenic arthritis (711.0) (M00) 0 0.0 1 0.7 1 0.4
Systemic lupus erythematosus (710.0) (M32) 5 3.6 3 2.1 8 2.8
Systemic sclerosis (710.1) (M34) 0 0.0 5 3.4 5 1.8
Pathological fracture (733.1) (M84.4) 0 0.0 1 0.7 1 0.4
Diseases of the genitourinary system (580-629) (N00-N99) 3 2.2 6 4.1 9 3.2
Renal failure (584-586) (N17-N19) 0 0.0 3 2.1 3 1.1
TOTAL 138 100.0 146 100.0 284 100.0
Source: Fundação Sistema Estadual de Análise de Dados (SEADE)
Rubrics and codes of the International Classification of Diseases, Injuries and Causes of Death, Ninth Revision (1985 to 1995)
Rubrics and codes of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (1996 to 2007)
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Table 4 Variables (n (%)) related to neoplams jointly listed with dermatomyositis and polymyositis in death
certificates, state of São Paulo, Brazil, 1985 to 2007
Variables Dermatomyositis Polymyositis Total
NEOPLAMS AS AN CAUSE OF DEATH
Underlying 13 (36.1) 0 (0.0) 13 (23.2)
Associated (Non-underlying) 23 (63.9) 20 (100.0) 43 (76.8)
Total 36 (100.0) 20 (100.0) 56 (100.0)
STANDARDIZED MORTALITY RATES (PER 1 000 000 POPULATION)
Value 0.0446 0.0249 0.0695
Confidence interval ± 95% 0.0300-0.0591 0.0140-0.0359 0.0512-0.0877
GENDER
Male 8 (22.2) 8 (40.0) 16 (28.6)
Female 28 (77.8) 12 (60.0) 40 (71.4)
Total 36 (100.0) 20 (100.0) 56 (100.0)
Ratio F:M 3.5:1 1.5:1 2.5:1
AGE AT DEATH (YEARS)
Mean (Standard deviation) 61.50 (± 13.66) 61.05 (± 15.82) 61.34 (± 14.38)
Median 64.50 64.50 64.50
Mode 50.50 54.50 50.50
SITES (CID-9) (CID-10)
Digestive organs (150-159) (C15-C26) 9 (25.0) 3 (15.0) 12 (21.4)
Stomach (151.9) (C16.9) 2 (5.6) 0 (0.0) 2 (3.6)
Duodenum (152.0) 1 (2.8) 0 (0.0) 1 (1.8)
Colon (C18.9) 1 (2.8) 1 (5.0) 2 (3.6)
Rectum (154.1) 1 (2.8) 0 (0.0) 1 (1.8)
Intestine (159.0) 1 (2.8) 0 (0.0) 1 (1.8)
Unspecified digestivo organ (159.9) 0 (0.0) 1 (5.0) 1 (1.8)
Billiary tract (C24.9) 1 (2.8) 0 (0.0) 1 (1.8)
Spleen (C26.1) 1 (2.8) 0 (0.0) 1 (1.8)
Breast (174) (C50) 8 (22.2) 4 (20.0) 12 (21.4)
Female genital organs (179-189) (C51-C58) 7 (19.4) 1 (5.0) 8 (14.3)
Cervix uteri (180.9) (C53.9) 2 (5.6) 1 (5.0) 3 (5.4)
Ovary (183.0) (C56) 5 (13.9) 0 (0.0) 5 (8.9)
Lung (162.9) (C34) 4 (11.1) 2 (10.0) 6 (10.7)
Lymphoid, haematopoetic and related tissues (200-208) (C81-C96) 3 (8.3) 3 (15.0) 6 (10.7)
Hodgkin’s disease (C81.9) 0 (0.0) 1 (5.0) 1 (1.8)
Non-Hodgkin’s lymphoma (202.8) (C85.9) 3 (8.3) 0 (0.0) 3 (5.4)
Myeloid leukaemia (C92.1) 0 (0.0) 1 (5.0) 1 (1.8)
Polycythaemia vera (D45) 0 (0.0) 1 (5.0) 1 (1.8)
Urinary tract (188-189) (C64-C68) 2 (5.6) 2 (10.0) 4 (7.1)
Kidney (189.0) 0 (0.0) 1 (5.0) 1 (1.8)
Bladder (C67.9) 2 (5.6) 1 (5.0) 3 (5.4)
Other 3 (8.3) 5 (25.0) 8 (14.3)
Base of tongue (C01) 1 (2.8) 0 (0.0) 1 (1.8)
Prostate (185.9) 0 (0.0) 1 (5.0) 1 (1.8)
Kaposi’s sarcoma (C46.9) 0 (0.0) 1 (5.0) 1 (1.8)
Abdomen (195.2) 0 (0.0) 1 (5.0) 1 (1.8)
Malignant neoplasm without specification of site (199) (C80) 2 (5.6) 2 (10.0) 4 (7.1)
Total 36 (100.0) 20 (100.0) 56 (100.0)
Source: Fundação Sistema Estadual de Análise de Dados (SEADE)
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behavior of dermatomyositis- and polymyositis-related
mortality. Therefore, we will draw comparisons with the
studies conducted in the United States, notwithstanding
the limitations regarding mortality statistics, the struc-
ture of the respective populations and the time differ-
ence between the compared periods. For
dermatomyositis as the underlying cause of death, the
mortality rates for men and women in the United States
were, respectively, 0.3 and 0.6 per 1,000,000 population
in the 1959-1961 period [7], higher than the 0.10 and
0.35 per 1,000,000 population we determined for the
state of São Paulo in the 1985-2007 period. However,
the study of the mortality rates for dermatomyositis and
polymyositis as the underlying cause of death in the
United States between 1968 and 1978 showed only gen-
der- and race-specific mortality rates [39]. Therefore,
the mortality rate for the general population in that per-
iod was recalculated, resulting in a crude mortality rate
of 1.55/1,000,000 population, also higher than the 0.44/
1,000,000 population we observed for the state of São
Paulo in the study period.
In the present study, the standardized dermatomyosi-
tis- or polymyositis-related mortality rates were consis-
tently higher for women than for men, a finding that is
consistent with the greater proportion of women
reported in previous studies on mortality [4,39], as well
as in studies involving patients with dermatomyositis or
polymyositis [1,3,8,37,38,43-47]. The higher dermato-
myositis- and polymyositis-related mortality among
women is related to higher prevalence of the diseases in
the female gender.
Our observation that the highest specific mortality
rates were among older individuals is consistent with
the results of the studies conducted in the United States
and in France [39,48]. In dermatomyositis and polymyo-
sitis, age is considered one of the factors that are prog-
nostic of lower survival and a greater risk of death. The
finding that the age at death was lower among dermato-
myositis-related deaths than among polymyositis-related
deaths might be due to the fact that dermatomyositis
has an earlier onset [37,47]. However, the temporal
increase in the mean age at death among women who
died from polymyositis is primarily due to the increase
in life expectancy for women in the state of São Paulo,
which rose from 70.02 to 77.98 years between 1980 and
2007.
Mortality statistics, like the used in this study, suffer
from two types of limitations: quantitative and qualita-
tive. In the State of São Paulo, the quantitative limita-
tions relating to the coverage of the number of deaths
that occur are unimportant. The relationship between
the deaths informed to SEADE Foundation and those
estimated by means of demographic projections avail-
able for recent years shows figures even above 100%,
which suggests that the mortality data coverage is very
good [49]. With regard to the qualitative limitations in
this State, ill-defined causes were considered to be the
underlying cause of death in only 6.11% and 6.41%, in
relation to the total number of deaths for the 1985-1995
and 1996-2007 periods, respectively–values that are
lower by half than those reported for the country as a
whole [50-52]. Furthermore, no difficulties were pre-
sented in transforming the causes of death into ICD
codes, among the death certificates mentioning derma-
tomyositis and polymyositis. It has been seen that the
coding work was accurate and did not constitute a
source of error that might have compromised the qual-
ity of the mortality statistics [18]. The processing of the
causes of death at the SEADE Foundation was per-
formed in accordance with the recommendations of the
WHO for the identification of the underlying cause of
death, and there was rigorous quality control of the
automatic data processing. An important limitation
refers to the fact of dermatomyositis and polymyositis
not being recorded anywhere by physicians that com-
plete death certificates of deceased patients. To our
knowledge this problem has not been studied to date
for these causes of death. Notwithstanding, the lack of
attention to mortality outcomes has been justified by
the argument that death certificates of patients with
chronic rheumatic diseases do not mention rheumatic
diseases at all [6].
One of the principal resources derived from the use of
multiple cause of death analysis is the recovery of data
related to the associated causes of death listed in the
medical certification section of the death certificate.
Greater understanding of the natural history of myopa-
thies translates to increased patient survival [44]. Knowl-
edge of the associated causes, resulting from
concomitant diseases [38], opens new perspectives for
the prevention of death primarily attributed to dermato-
myositis or polymyositis. Pneumonia, which is one of
the principal associated causes, is particularly important
due to the fact that its severity increases when it occurs
jointly with septicemia, as shown in the present study.
The factors predisposing to infectious complications
include esophageal, muscular and pulmonary involve-
ment, as well as the use of immunosuppressants [53]. In
France, infectious complications were found to be prin-
cipal immediate cause of death in patients with derma-
tomyositis or polymyositis, occurring in approximately
45.8% [54]. However, despite the fact that, on death cer-
tificates in Brazil, respiratory failure is frequently listed
as an immediate cause of death [52], we found that it
was often mentioned jointly with pneumonia. Interstitial
lung disease and related conditions occurred with
greater frequency in dermatomyositis than in polymyosi-
tis. Together, pneumonia, respiratory failure and
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interstitial lung disease/related conditions represent the
greatest risk of death in patients with septicemia, and
respiratory impairment has been reported to occur in
up to 70% of such patients [4,55], the lungs being the
organ system most often affected by diseases accompa-
nying myopathies [38].
We also found that circulatory diseases were common
associated causes of death–heart failure, arrhythmias,
arterial hypertension, coronary ischemia and cardiore-
spiratory arrest prevailing as the most common immedi-
ate causes of death. These findings are consistent with
reports that up to 75% of patients with myositis present
cardiovascular involvement [56,57].
Table 4 presents the underlying causes of death for
the deaths in which dermatomyositis and polymyositis
were identified as associated causes. Considering the
chapters of the ICD, neoplasm, diseases of the respira-
tory system and diseases of the circulatory system,
together with certain infectious diseases and parasitic
diseases, predominate. Many of the underlying causes of
death included in Table 4 were also listed as associated
causes, an eventuality that depends greatly on the weight
that the physician gives to a particular condition, on the
way in which the medical certification section of the
death certificate is filled out and on the WHO guide-
lines and mortality standards regarding the condition.
These considerations primarily apply to conditions
inherent to the natural history of dermatomyositis and
polymyositis. Chief among the deaths from infectious
diseases were those attributed to tuberculosis and those
attributed to AIDS. Characteristic of the overlap syn-
drome, there were deaths in which the death certificate
listed systemic lupus erythematosus or systemic sclerosis
as the underlying cause of dermatomyositis or
polymyositis.
The mean number of causes of death listed per death
certificate constitutes one of the principal indicators
regarding multiple cause of death analysis [14,15,18]. In
the present study, the consideration of only the underly-
ing cause of death would have resulted in the loss of
approximately two causes of death per death certificate.
The lower mean number of causes on the death certifi-
cates on which dermatomyositis or polymyositis was
listed as the underlying cause is attributable to the
greater proportion of death certificates listing only one
or two causes, unlike the death certificates listing der-
matomyositis or polymyositis as associated causes, on
which three or four causes were needed in order to
describe the underlying cause. However, the greater
mean number of causes in the 1996-2007 period is pri-
marily due to the new line (d) introduced into the medi-
cal certification section of the death certificate when the
ICD-10 entered into effect, as well as to better comple-
tion of the death certificates by physicians [13,18].
Nevertheless, the mean number of causes listed on the
death certificates related to deaths from dermatomyosi-
tis or polymyositis, except for those on which dermato-
myositis was listed as the underlying cause, is higher
than that found for the state of São Paulo or for Brazil
as a whole, which was 3.15 ± 1.37 and 2.81 ± 1.38,
respectively, in 2003 [18].
The greater risk of death linked to dermatomyositis
accompanied by neoplasm was consistent with the
results of an earlier study [58], in which the mortality
data were decisive in elucidating the risk of neoplasm in
patients with dermatomyositis [34,58,59]. In addition,
we found that, among the deaths related to dermato-
myositis, the mean age at death was higher in those
with a joint mention of neoplasm that in those in which
neoplasm was not mentioned. This was also observed in
patients in Spain, Hungary and France, where the mean
and median ages, as well as the sites of the neoplasms,
were quite similar to those found in the present study
[47,48,60-62].
Conclusions
In the present study, we have used multiple cause of
death analysis to describe the characteristics of dermato-
myositis- and polymyositis-related mortality over the
course of the 23-year study period (1985-2007). We find
it worrisome that dermatomyositis or polymyositis was
identified as the underlying cause of death in only 55.2%
of the deaths studied. This indicates that both diseases
were underestimated in the primary mortality statistics.
We also observed a predominance of deaths in women
and in older individuals, as well as a trend toward stabi-
lity in the mortality rates, except for a drop observed in
the mortality rates for polymyositis in men, as the
underlying cause and in terms of the total number of
mentions. The investigation of the underlying and asso-
ciated causes of death related to dermatomyositis or
polymyositis broaden the knowledge of the natural his-
tory of both diseases. We have confirmed that the risk
of death is greater when either disease is accompanied
by neoplasm, albeit to lesser degree in individuals with
polymyositis. The results of the present study could help
integrate mortality data for use in the evaluation of con-
trol measures for dermatomyositis and polymyositis.
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